A220 CHIMIA 2016, 70, No. 3 COMMUNITY NEWS



Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Invitation to the SCS General Assembly 2016



The Board of Directors invites all members of the Swiss Chemical Society and the delegates of its associated societies to the 26th General Assembly.

April 22, 2016, 13.30–14.00h Lecture Hall G 45, Irchel Campus University of Zürich, Winterthurerstrasse 190, 8057 Zürich

Agenda

- 1. Welcome and approval of the agenda
- 2. Election of the vote counters
- 3. Minutes of the 25th General Assembly from April 24, 2015 in Basel (published in CHIMIA 5/2015, A305)
- 4. Annual report 2015 (published in CHIMIA 1-2/2016)
- 5. Financial statement 2015 incl. audit report
- 6. Discharge the Board
- 7. Elections
- 8. News and strategic projects
- 9. Outlook 2016/17
- 10. Varia

Motions to the assembly can be submitted until April 10, 2016 to info@scg.ch. A summary of the financial statement 2015 will be published on the homepage as news message after the formal audit.

Swiss Chemical Society (SCS)

Dr. Alain De Mesmaeker David Spichiger Executive Director

Further education courses provided by DAS



The Division of Analytical Sciences (DAS) provides a wide range of further education courses that target beginners as well as experts. In collaboration with industrial and academic partners, DAS organizes more than 50 courses from April to November 2016 and focus on the following topics:

- Separation
- Spectroscopy
- Analytical application
- Methods of live sciences
- · Quality assurance and information management

SCS members and members from partner societies profit from reduced course fees.

Visit the website to get more information: www.scg.ch/courses

Ausschreibung: SCG FH-Award 2016



Die ILMAC setzt als Fachmesse für Labor- und Prozesstechnologie im Bereich Chemie stark auf industrienahe Innovationen und Anwendungen. Fachhochschulen fokussieren sich in der Ausbildung wie in der Forschung & Entwicklung speziell auf diese Aspekte. Der 2013 eingeführt SCG FH-Award wird zum zweiten Mal ausgeschrieben

und im Rahmen der ILMAC 2016 prämiert. Alle Projekte werden am Gemeinschaftsstand der Fachhochschulen und der SCG ausgestellt und die Siegerprojekte zusätzlich im ILMAC-Forum präsentiert.

Prämierungskriterien: «Innovation & Anwendung». Das angemeldete Projekt setzt auf Innovation und deren praktische Anwendung und Umsetzung beim Industriepartner. Das Projekt muss in einem der drei folgenden Themenbereiche angesiedelt sein:

- Analytik und Food Science. Entwicklung allgemeiner Analysetechniken und Anwendungsmethoden für die Lebensmittelbranche.
- Biotechnologie und Bioanalytik. Entwicklung von Geräten und Methoden für Anwendungen im Bereich Biotechnologie, Diagnostik und Medizin.
- Prozess- und Verfahrenstechnik. Chemische oder biochemische Anwendungen in den Bereichen Prozess- und Verfahrenstechnik.

Projekte für den SCG FH-Award 2016 müssen bis 17.06.16 eingereicht werden. Weiter Details auf www.scg.ch/scs-fh-award

DIAC besucht das Werk BASF Kaisten am 7. April, inkl. Mitgliederversammlung 2016

Wir freuen uns, Sie zur Mitgliederversammlung 2016 der Division Industrielle und Angewandte Chemie einzuladen.

Donnerstag, 7. April 2016, ab 9.30 Uhr bei BASF Kaisten, Hardmattstrasse 434, 5082 Kaisten

Auch dieses Jahr können wir Ihnen gleichzeitig einen Besuch in einer chemischen Produktionsanlage anbieten. Für den Werksrundgang in der BASF-Metilox-Anlage bitten wir Sie, Ihre persönliche Schutzausrüstung (Helm, Kittel, Brille) sowie Sicherheitsschuhe mitzubringen, sofern vorhanden. Es hat vor Ort nur eine beschränkte Anzahl zur Verfügung.

Nebst dem Firmenporträt, vorgestellt von *Kristian Hall*, Werkleiter BASF, wird uns Dr. *Andreas Brodthagen* der BASF Forschung ein spannendes Referat zum Thema

«Smart Scale Production» (modulare Produktionskonzepte)


halten. Die Besichtigung der Metilox Produktion und Verpackung am Nachmittag wird uns exklusive Einblicke in eine chemische Produktionsanlage erlauben. COMMUNITY NEWS CHIMIA 2016, 70, No. 3 A221

Der Vorstand der DIAC hofft, Sie recht zahlreich am 7. April 2016 begrüssen zu dürfen.

Weiter Details finden Sie auf www.scg.ch/diac

Freundliche Grüsse Dr. Bernhard Urwyler, Präsident

SCS Fall Meeting 2016: Call for Contributions is open



The Swiss Chemical Society Fall Meeting is the largest annual scientific event in Switzerland. It offers a unique opportunity for graduate students, post-doctoral researchers and scientists of all levels, from both, academia and industry, to share the results of their research projects. It also stimulates the exchange of ideas between all generations of

chemists, often creating the seeds for new projects and collaborations.

University of Zurich, Irchel Campus September 15, 2016, 09.00–18.30

One of the highlights of this year's Fall Meeting will be the Paracelsus Award Lecture presented by Prof. Michael Graetzel of the EPF Lausanne. The Scientific Program will offer invited and contributed lectures as well as poster presentations in the following areas of chemistry:

- Analytical Sciences
- Catalysis Science & Engineering
- Computational Chemistry
- Inorganic & Coordination Chemistry
- · Medicinal Chemistry & Chemical Biology
- · Organic Chemistry
- Physical Chemistry
- Polymers, Colloids & Interfaces.

As in previous years, the best poster presentations and oral contributions in each session will be awarded prizes. There will also be a Commercial Exhibition.

We encourage you to come to Zürich to present your research and to be part of a vibrant meeting.

The call for contributions is open from March 21 – May 20, 2016 http://scg.ch/fallmeeting/2016

EuCheM Congress: Important Reminder Call for Abstracts



On behalf of EuCheMS, ANQUE and all the Spanish societies involved in the organisation of this EuCheMS Congress, you are warmly invited to the 6th European Congress of Chemistry (EuCheMS 2016) in Seville, Spain, 11th–15th September, 2016.

Plans are already developing to have a wonderful celebration of Chemistry, the science that most enhances the everyday lives for every one of us, in all its facets. Plenary, Invited and Contributed lectures will bring you up to date in

all topical areas of modern fundamental and applied Chemistry and will be offered by some of Europe's and the world's most distinguished Chemists.

You too can participate! There will be plenty of opportunities for contributed papers and posters. Guidelines, information for authors, submissions, themes, topics, sessions and important dates are published on the website.

Access the Abstract submission form available on line.

Submission Deadline: April 1st, 2016

You can find all information at the web page:

http://euchems-seville2016.eu/

Basel Life Science Week 2016 – Registration & Abstract Submission now open!



The BLSW Committee has compiled a highly interesting and diverse scientific programme for this year's congress and we are delighted to announce that the Basel Life Science Week 2016 Preliminary Scientific Programme is now available on the congress website.

Share your research and best-practices in diverse aspects of Life Science at BLSW 2016; the ideal platform for you to present your latest findings and experiences to key international specialists. To view all abstract topics and preparation guidelines please click here.

Deadline for abstract submission is 21st April 2016

The registration is free of charge for all participants in case you register until 18th September 2016. The registration includes: access to all scientific sessions and to the industrial exhibition, to the social programme such as: welcome reception, interactive poster session and reception. All delegates will receive a programme at a glance as well as coffee and lunch in the exhibition area.

Please visit the congress website www.basel-life-science-week.eu for further information.

Martin Vetterli will be the next president of EPFL



The new president of the Ecole Polytechnique Fédérale de Lausanne (EPFL) was announced on Feb 26, 2016, by the Swiss Federal Council, which confirmed the proposal submitted by the ETH Board. Martin Vetterli will assume his duties on 1 January 2017, taking over for outgoing president Patrick Aebischer.

The president of the National Research Council of the Swiss National Science Foundation and a professor in communication systems at EPFL, Martin Vetterli, 58 years old, is a brilliant researcher, an accomplished teacher and a recognized expert in the Swiss education and research sector. He was appointed by the Federal Council following a selection process conducted by the ETH Board. Professor Vetterli received the unanimous support of the ETH Board.

Born in Solothurn on 4 October 1957, Professor Vetterli received his elementary and secondary education in the Canton of Neuchâtel. He earned a Bachelor's degree in electrical engineering from the ETH Zurich (ETHZ) in 1981, a Master's of Science degree from Stanford University in 1982, and a PhD from EPFL in 1986. Professor Vetterli taught at Columbia University as an assistant and then associate professor. He was subsequently named full professor in the Department of Electrical Engineering and Computer Sciences at the University of California at Berkeley before returning to EPFL as a full professor at the age of 38. He has also taught at ETHZ and Stanford University. *Source: www.epfl.ch*

A222 CHIMIA 2016, 70, No. 3 COMMUNITY NEWS

The Essential Chemical Industry - online

This is a reference library of the world's principal industrial chemicals, their uses and their manufacture using current industrial processes and innovations. This new web-based edition has been developed from the latest edition of a book of the same title. It is intended for:

- school, college and university students and their teachers
- industrial chemists and employees of chemical companies needing a quick reference or overview

This online version adds, as well as updates, exciting interactive research capability to this internationally-renowned educational publication.

Source: http://www.essentialchemicalindustry.org

A warm welcome to our new members!

Period: 23.01.2016 - 25.02.2016

Manon Briand, Küsnacht – Amanda Cook, Zürich – Camilla Corsi, Basel – Stefan Diethelm, Allschwil – Marco Etter, Winterthur – Juliane Glüge, Zürich – Andreas Hafner, Basel – Pawel Lewandowski, Beromünster – Markus Müller, Frauenfeld – Margherita Pucino, Zürich – Chiara Saggese, Lausanne – Keith Searles, Zürich.

Keine halben Sachen.



Die Welt ist voll von Halbwissen. Besonders im sensiblen Umfeld der Chemie ist dies jedoch fehl am Platz. Deshalb arbeiten wir seit 1947 mit Leidenschaft und Liebe zum Detail daran, dass evaluierte Daten und Fakten rund um das Themenfeld Chemie zur Verfügung stehen. Immer. Und ohne Ausnahme. So wurde "Der RÖMPP" Synonym für inzwischen über 65 000 Stichwörter und über 240 000 Querverweise, auf die man sich verlassen kann. Das sollten Sie sich am besten selbst anschauen.

Sonderkonditionen für SCG-Mitglieder.

Nur 100% sind 100%. www.roempp.com



"Geschichte der Chemie", eine Vorlesung an der Universität Freiburg aus dem Jahr 1963

Die SCG veröffentlichte am 11.02.2016 auf ihrere Website (www.scg.ch) den Mitschnitt einer einsemestrigen Gastvorlesung "Geschichte der Chemie" im Sommersemester 1963 im Chemischen Institut der Universität Freiburg im Breisgau durch Herrn Professor Witzinger-August von der Universität Basel.

Die Aufnahmen stammen von Dr. Albrecht Kolb aus Weisenheim am Berg (D), der die Bänder der SCG freundlicherweise zur Verfügung gestellt hat. Er sagt dazu: "Ich meine, die Bänder sind ein gutes Zeitdokument. Wahrscheinlich wird sich die Betrachtungsweise der geschichtlichen Dinge zum Teil geändert haben. Aber Herr Professor Witzinger erzählt nicht nur Chemiegeschichte, er würzt die Vorlesung ja auch mit Histörchen, philosophischen Gedanken und witzigen Bemerkungen, die trockenes Wissen so vergnüglich machen. Und vermitteln so auch den ihm eigenen "Witzinger-Sound". Ich hoffe, die jetzigen Hörer haben auch so viel Spass wie das damalige Auditorium, wie zu hören ist."

HONORS AND AWARDS

David Calligaris receives Analytical and Bioanalytical Chemistry Best Paper Award 2015



Biochemist honoured for his research in the use of mass spectrometry in the diagnosis of brain neoplasms during surgery

David Calligaris is the winner of this year's ABC Best Paper Award, presented by the Springer journal Analytical and Bioanalytical Chemistry. In a paper published in ABC, lead author Calligar-

is and his colleagues describe a novel system using mass spectrometry as an intraoperative tool. Their method opens new possibilities to detect additional tumour markers which are useful in diagnosing brain and breast tumours during surgery. The award, accompanied by 1,500 euros, was created by Springer to honour exceptional young scientists and to stimulate their research careers. The ABC Best Paper Award has been given since 2005. Source: Springer Verlag, Heidelberg | New York

Dr. Peter Kraus receives the Justin Jankunas Doctoral Dissertation Award

Dr. Peter Kraus receives the Justin Jankunas Doctoral Dissertation Award of the American Physical Society. He is awarded for his dissertation, "Studies of Electronic and Nuclear Structure and Dynamics by High Harmonic Spectroscopy," which he wrote under the direction of Prof. Hans Jakob Wörner at ETH Zürich. He will present his work with two other winners at the DCP Plyler and Jankunis Prize Session, on Tuesday, March 15, 2016, at 11:15 a.m. in the Hilton Inner Harbor Holiday Ballroom IV. Source: https://www.chab.ethz.ch/

COMMUNITY News CHIMIA 2016, 70, No. 3 A223

JOURNALS

Chemistry - A European Journal, Special Issue: Women in Chemistry 2016



In 2011 Wiley-VCH published a special issue dedicated to Women in Chemistry as part of the IUPAC/UNESCO International Year of Chemistry initiative. As a follow up and to celebrate International Women's Day that was on March 8th 2016, Wiley-VCH published another issue dedicated to women from around the world currently working in chemical re-

search. Chemistry – A European Journal is proud to highlight the fantastic contributions women are making to chemistry and hopes that this special issue will help to inspire more young women currently studying at university to pursue a career in research.

http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-3765

Some Statistics 2015 on ChemPubSoc



In 2015 all ChemPubSoc Europe journals published together 6,236 articles (+3% from 6,063 in 2014); total submissions increased from 14,338 to 14,794 (+3.2%). Full text downloads (numbers according to Counter Compliant Standard) increased by more than double percentage, in total by 6.8% from 6,010,930 to 6,417,802 Mio. This can be taken as a

sign for the high quality as well as increased visibility via the Wiley online platform.

A lot of experiments are going on, like working with Social Media, article renting, and last but not least going mobile via Apps. ChemPubSoc Europe journals including ChemistryViews had for instance: 36,914 Facebook Likes (+174.8% from 21,116 in 2014), 12,282 Twitter Followers (+187.9% from 6,535 in 2014). The Apps for Chem PubSoc Europe journals excluding ChemistryViews were downloaded so far 52,116 times, we saw 235,407 page views from a total of 27,053 sessions in 2015.

The ranking for App installations and usage is (top down): European Journal of Organic Chemistry / Chemistry - A European Journal / ChemistryOpen / ChemBioChem / ChemPhysChem / ChemMedChem / European Journal of Inorganic Chemistry / ChemPlusChem / ChemCatChem / ChemSusChem / ChemElectroChem

INDUSTRIAL NEWS

Source: www.chemmanager-online.com et al.

Drug Firms Urge Governments to Fight Superbugs

Jan. 26, 2016: More than 80 international drug and biotechnology companies have urged governments to work with them to combat the emergence of drug-resistant superbugs, according to a report by news agency Reuters. In a declaration at the World Economic Forum in Davos, Switzerland, the companies called for coordinated efforts to cut unnecessary use of antibiotics and support the development of new ones.

Superbugs could kill tens of millions of people within decades unless new antibiotics are found, they said. The problem has risen in importance in recent years as many common infections are not responding to conventional drugs and drug companies have cut back on investment in this field. The discovery of a gene called mcr-1 in China that makes bacteria resistant to all known antibiotics has also rung alarm bells.

Andrew Witty, CEO of GlaxoSmithKline (GSK), said the difficulty of finding new antibiotics was highlighted by the fact that mass screenings of hundreds of millions of chemicals at GSK and two other large firms over nine years had yielded no potential new drugs. This, he said, was because it is an extremely difficult area to make progress in.

Companies that have signed the Davos declaration include Merck, Pfizer, Sanofi, Novartis and AstraZeneca, among others. In the pact, they pledged to encourage more appropriate use of antibiotics, including reduced use in livestock, better education of doctors and nurses, and improved infection control. They also urged more affordable access to antibiotics all over the world and better collaboration between researchers at drug companies and those at universities and governments.

GAVI and US Merck Link on Ebola Vaccine

Jan. 27, 2016: Geneva, Switzerland-based GAVI (Global Alliance for Vaccines and Immunization), a public-private partnership, and Merck Sharp & Dohme (MSD), known in the US as Merck & Co, have signed an agreement to support the provision of a vaccine against Ebola. The pact announced at the World Economic Forum in Davos, Switzerland, represents an advance purchase commitment by GAVI to help MSD take its vaccine candidate through late-stage clinical trials, licensing procedures and World Health Organization (WHO) prequalification.

Under the commitment, GAVI has provided \$5 million toward the development of MSD's Rvsv G-ZEBOV-GP live attenuated Ebola Zaire vaccine on the understanding that it will be submitted for licensure by the end of 2017. If approved, this would become one of the world's first licensed Ebola vaccines, and GA-VI would be able to begin purchasing the vaccine to build stocks in case the disease returns. MSD will ensure that 300,000 doses are available from May 2016 for expanded-use clinical trials and/ or emergency use as needed while development continues. Seth Berkley, CEO of GAVI, said the Ebola crisis is a wake-up call. "Our innovative financing agreement with Merck will ensure that we are ahead of the curve for future Ebola outbreaks," he added. The US drugmaker has already submitted an application through WHO's Emergency Use Assessment and Listing (EU-AL) process. If approved, the vaccine could be used if another Ebola outbreak occurs before a license is granted. Despite the vaccine still being under investigation, an interim analysis from a randomized phase III efficacy trial conducted in Guinea suggested that Rvsv G-ZEBOV-GP could be effective against Ebola Zaire. It is currently the only vaccine with published interim Phase III efficacy data. The Phase II trial is ongoing. Research evaluating Rvsv G-ZEBOV-GP also continues in Phase I, II and III clinical trials at sites in the EU, Africa, the US and Canada. Initially engineered by scientists from the Public Health Agency of Canada, Rvsv G-ZEBOV-GP was licensed to a subsidiary of NewLink Genetics. Merck & Co licensed the candidate from NewLink Genetics in late 2014 when the Ebola epidemic was at its worst. GAVI said it continues to work with all vaccine manufacturers, including GlaxoSmithKline (GSK) and Johnson & Johnson's ethical drugs arm Janssen, to advance development programs for an Ebola vaccine.

The Ebola epidemic in West Africa claimed the lives of more than 11,300 people and infected over 28,600. Although early-stage development of a vaccine started more than a decade

A224 CHIMIA 2016, 70, No. 3 COMMUNITY NEWS

ago, mainly to counter potential bioterrorism threats, no manufacturer had a vaccine in Phase III trials when the outbreak began.

DKSH in Distribution Deal with Hampford Research

Jan. 26, 2016: Switzerland's DKSH has signed an exclusive agreement with US specialty chemicals manufacturer Hampford Research Inc (HRI). Under the agreement, DKSH will supply, market and distribute HRI's photoactive technology products in Europe, North America and Asia. The deal includes HRI's entire line of ultraviolet/electron beam (UV/EB) products, including photo acid generators, photo initiators, monomers and co-initiators, as well as any future products created from customer-related product development.

HRI specializes in producing high-purity chemicals used in the electronics, dental, personal care, printing and imaging, and adhesives industries. End products include dental fillings and false teeth, cosmetics and hair products, sunscreen, smart phones, tablets and desktop computers, sticky-backed labels, holographic images and 3D prototype imaging.

Mike Wyrostek, HRI's director of sales and marketing, said the combination of HRI's custom manufacturing capabilities and DKSH's industry knowledge and contacts would result in many successes.

Lonza Expands Drug Product Services

Feb. 4, 2016: Swiss fine and specialty chemical producer Lonza is building up its capabilities for drug development and manufacturing services to meet customers' clinical outsourcing needs. The focus will be on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other administering routes. Options will be included for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules. The drug product services will be offered in the fourth quarter of this year from laboratories in Basel, Switzerland, and will initially center on formulation and analytical development, and quality control. Manufacturing capabilities for preclinical and clinical use will be available in late 2016.

Specialized services will also be available including: particulate identification, characterization and quantification; excipient and surfactant characterization; assessment of extractables and leachables; and testing of container closure integrity. Marc Funk, Lonza's chief operating officer, called the portfolio expansion an important step in becoming a one-stop-shop for all clinical outsourcing requirements. Hanns-Christian Mahler will head the drug product business. Mahler led the departments of pharmaceutical development & supplies and formulation R&D biologics at Swiss drugmaker Roche for 10 years.

AVA Biochem Adds FDCA to Boost Bio-plastics

Feb. 8, 2016: Swiss biochemical company AVA Biochem is adding furan derivative 2,5-furandicarboxylic acid (FDCA) to its product portfolio in order to support the development of biobased plastics. At its plant in Muttenz, Switzerland, the company is now producing FDCA from the oxidation of 5 (hydroxymethyl) furfural (5-HMF). The plant, which started operations in February 2014, produces 5-HMF from renewable feedstocks using AVA Biochem's proprietary hydrothermal processing technology. FDCA produced from 5-HMF can be used to make bio-based polyethylene furanoate (PEF) and other bio-plastics. AVA Biochem said these materials have a variety of sought-after advantages which will help bio-based plastics boost their share of the billion-dollar packaging market. The company said producing FCDA from 5-HMF on an industrial scale yielded significant cost advantages, paving the way for competitively priced biobased packaging in the future.

AVA Biochem's chief marketing officer Thomas Kläusli said the addition of FDCA was an important milestone for the company. "This will significantly accelerate market development of 100% bio-based plastic packaging based on PEF, a renewable replacement material for polyethylene terephthalate (PET)," he said. The company will now supply FDCA to companies engaged in the research and development of new products.

According to AVA Biochem, furan derivatives produced from renewable carbohydrates are some of the most important next-generation platform chemicals. In 2004, the US Department of Energy classed FDCA as one of the 12 most important platform chemicals globally.

Biosynth Continues to Grow

Feb 17, 2016: The Swiss fine chemical group, Biosynth, with its headquarters and a production site in Staad, Switzerland has expanded its business presence to Slovakia to meet with growing business activity and demands for its products in the global market. The new office in Bratislava is a valuable addition to the Biosynth organization which already has locations in Germany and the USA as well as intensive commercial activities in China. This recent move marks another step in a comprehensive expansion strategy in which Eastern Europe and in particular, Slovakia, plays an important role. The company will benefit from highly skilled employees and an attractive business environment that Slovakia can offer.

In the meantime, Biosynth has also continued to invest in the Staad location. The workforce was increased in 2015 and this trend will continue throughout 2016.

Source: https://www.biosynth.com/

